- Home
- HCKT vs TRVI Comparison
HCKT vs TRVI Comparison
Compare HCKT & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCKT
- TRVI
- Stock Information
- Founded
- HCKT 1991
- TRVI 2011
- Country
- HCKT United States
- TRVI United States
- Employees
- HCKT N/A
- TRVI N/A
- Industry
- HCKT Professional Services
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- HCKT Consumer Discretionary
- TRVI Health Care
- Exchange
- HCKT Nasdaq
- TRVI Nasdaq
- Market Cap
- HCKT 703.0M
- TRVI 725.7M
- IPO Year
- HCKT 1998
- TRVI 2019
- Fundamental
- Price
- HCKT $25.85
- TRVI $6.24
- Analyst Decision
- HCKT Strong Buy
- TRVI Strong Buy
- Analyst Count
- HCKT 3
- TRVI 9
- Target Price
- HCKT $31.33
- TRVI $19.94
- AVG Volume (30 Days)
- HCKT 217.5K
- TRVI 1.6M
- Earning Date
- HCKT 08-05-2025
- TRVI 08-07-2025
- Dividend Yield
- HCKT 1.86%
- TRVI N/A
- EPS Growth
- HCKT N/A
- TRVI N/A
- EPS
- HCKT 0.84
- TRVI N/A
- Revenue
- HCKT $307,532,000.00
- TRVI N/A
- Revenue This Year
- HCKT $6.06
- TRVI N/A
- Revenue Next Year
- HCKT $5.46
- TRVI N/A
- P/E Ratio
- HCKT $30.74
- TRVI N/A
- Revenue Growth
- HCKT 3.49
- TRVI N/A
- 52 Week Low
- HCKT $21.13
- TRVI $2.36
- 52 Week High
- HCKT $34.02
- TRVI $7.48
- Technical
- Relative Strength Index (RSI)
- HCKT 58.74
- TRVI 53.18
- Support Level
- HCKT $25.10
- TRVI $5.41
- Resistance Level
- HCKT $26.09
- TRVI $6.08
- Average True Range (ATR)
- HCKT 0.61
- TRVI 0.30
- MACD
- HCKT 0.15
- TRVI 0.04
- Stochastic Oscillator
- HCKT 91.39
- TRVI 83.15
About HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.